|Day Low/High||18.16 / 18.66|
|52 Wk Low/High||8.98 / 21.92|
Retrophin (RTRX), the biotech company that used to be run by indicted hedge fund manager Martin Shkreki, provides an interesting investment opportunity.
The meteoric rise of the young, brazen, entrepreneur seemed like it would inevitably end in handcuffs.
The SEC charged the controversial health care CEO with committing fraud over a five-year period.
Only one fund category (of 20) has beaten the S&P 500 over half a decade.